Follow CVALF to never miss an important update.
The company reported earnings of 7 cents per share, which was much higher than the roughly 1 cent analysts expected. Revenue came in at about 10 million dollars, matching what the market anticipated. This performance shows the company is successfully turning its patented medical coatings and dressings into a profitable business after years of losses.
These results support the view that Covalon is becoming a more stable medical device player. By focusing on specialized products for high-stakes hospital areas like pediatric intensive care, the company is building a base of recurring sales. The big jump in profit per share suggests that as revenue grows, more of that money is reaching the bottom line.
Management has cleared the bar in six of the last seven quarters, often by wide margins. The business is currently outrunning analyst forecasts as it shifts into a more profitable phase.
| Expectation | |
|---|---|
| EPS | $0.03 |
| Revenue | $7M |